Copyright Reports & Markets. All rights reserved.

Global Islet Amyloid Polypeptide Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Islet Amyloid Polypeptide Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Islet Amyloid Polypeptide Market Size Growth Rate by Product
      • 1.4.2 AC-253
      • 1.4.3 DACRA-042
      • 1.4.4 DACRA-089
      • 1.4.5 KBP-056
      • 1.4.6 KBP-088
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Islet Amyloid Polypeptide Market Size Growth Rate by End User
      • 1.5.2 Metabolic Disorders
      • 1.5.3 Gastrointestinal
      • 1.5.4 Musculoskeletal Disorders
      • 1.5.5 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Islet Amyloid Polypeptide Market Size
      • 2.1.1 Global Islet Amyloid Polypeptide Revenue 2014-2025
      • 2.1.2 Global Islet Amyloid Polypeptide Sales 2014-2025
    • 2.2 Islet Amyloid Polypeptide Growth Rate by Regions
      • 2.2.1 Global Islet Amyloid Polypeptide Sales by Regions
      • 2.2.2 Global Islet Amyloid Polypeptide Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Islet Amyloid Polypeptide Sales by Manufacturers
      • 3.1.1 Islet Amyloid Polypeptide Sales by Manufacturers
      • 3.1.2 Islet Amyloid Polypeptide Sales Market Share by Manufacturers
      • 3.1.3 Global Islet Amyloid Polypeptide Market Concentration Ratio (CR5 and HHI)
    • 3.2 Islet Amyloid Polypeptide Revenue by Manufacturers
      • 3.2.1 Islet Amyloid Polypeptide Revenue by Manufacturers (2014-2019)
      • 3.2.2 Islet Amyloid Polypeptide Revenue Share by Manufacturers (2014-2019)
    • 3.3 Islet Amyloid Polypeptide Price by Manufacturers
    • 3.4 Islet Amyloid Polypeptide Manufacturing Base Distribution, Product Types
      • 3.4.1 Islet Amyloid Polypeptide Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Islet Amyloid Polypeptide Product Type
      • 3.4.3 Date of International Manufacturers Enter into Islet Amyloid Polypeptide Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Islet Amyloid Polypeptide Sales by Product
    • 4.2 Global Islet Amyloid Polypeptide Revenue by Product
    • 4.3 Islet Amyloid Polypeptide Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Islet Amyloid Polypeptide Breakdown Data by End User

    6 North America

    • 6.1 North America Islet Amyloid Polypeptide by Countries
      • 6.1.1 North America Islet Amyloid Polypeptide Sales by Countries
      • 6.1.2 North America Islet Amyloid Polypeptide Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Islet Amyloid Polypeptide by Product
    • 6.3 North America Islet Amyloid Polypeptide by End User

    7 Europe

    • 7.1 Europe Islet Amyloid Polypeptide by Countries
      • 7.1.1 Europe Islet Amyloid Polypeptide Sales by Countries
      • 7.1.2 Europe Islet Amyloid Polypeptide Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Islet Amyloid Polypeptide by Product
    • 7.3 Europe Islet Amyloid Polypeptide by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Islet Amyloid Polypeptide by Countries
      • 8.1.1 Asia Pacific Islet Amyloid Polypeptide Sales by Countries
      • 8.1.2 Asia Pacific Islet Amyloid Polypeptide Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Islet Amyloid Polypeptide by Product
    • 8.3 Asia Pacific Islet Amyloid Polypeptide by End User

    9 Central & South America

    • 9.1 Central & South America Islet Amyloid Polypeptide by Countries
      • 9.1.1 Central & South America Islet Amyloid Polypeptide Sales by Countries
      • 9.1.2 Central & South America Islet Amyloid Polypeptide Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Islet Amyloid Polypeptide by Product
    • 9.3 Central & South America Islet Amyloid Polypeptide by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Islet Amyloid Polypeptide by Countries
      • 10.1.1 Middle East and Africa Islet Amyloid Polypeptide Sales by Countries
      • 10.1.2 Middle East and Africa Islet Amyloid Polypeptide Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Islet Amyloid Polypeptide by Product
    • 10.3 Middle East and Africa Islet Amyloid Polypeptide by End User

    11 Company Profiles

    • 11.1 Adocia SAS
      • 11.1.1 Adocia SAS Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Adocia SAS Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Adocia SAS Islet Amyloid Polypeptide Products Offered
      • 11.1.5 Adocia SAS Recent Development
    • 11.2 AstraZeneca Plc
      • 11.2.1 AstraZeneca Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AstraZeneca Plc Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AstraZeneca Plc Islet Amyloid Polypeptide Products Offered
      • 11.2.5 AstraZeneca Plc Recent Development
    • 11.3 Eli Lilly and Co
      • 11.3.1 Eli Lilly and Co Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Eli Lilly and Co Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Eli Lilly and Co Islet Amyloid Polypeptide Products Offered
      • 11.3.5 Eli Lilly and Co Recent Development
    • 11.4 Neurimmune Holding AG
      • 11.4.1 Neurimmune Holding AG Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Neurimmune Holding AG Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Neurimmune Holding AG Islet Amyloid Polypeptide Products Offered
      • 11.4.5 Neurimmune Holding AG Recent Development
    • 11.5 Nordic Bioscience A/S
      • 11.5.1 Nordic Bioscience A/S Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Nordic Bioscience A/S Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Nordic Bioscience A/S Islet Amyloid Polypeptide Products Offered
      • 11.5.5 Nordic Bioscience A/S Recent Development
    • 11.6 Prothena Corp Plc
      • 11.6.1 Prothena Corp Plc Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Prothena Corp Plc Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Prothena Corp Plc Islet Amyloid Polypeptide Products Offered
      • 11.6.5 Prothena Corp Plc Recent Development
    • 11.7 reMYND NV
      • 11.7.1 reMYND NV Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 reMYND NV Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 reMYND NV Islet Amyloid Polypeptide Products Offered
      • 11.7.5 reMYND NV Recent Development
    • 11.8 Zealand Pharma AS
      • 11.8.1 Zealand Pharma AS Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Zealand Pharma AS Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Zealand Pharma AS Islet Amyloid Polypeptide Products Offered
      • 11.8.5 Zealand Pharma AS Recent Development

    12 Future Forecast

    • 12.1 Islet Amyloid Polypeptide Market Forecast by Regions
      • 12.1.1 Global Islet Amyloid Polypeptide Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Islet Amyloid Polypeptide Revenue Forecast by Regions 2019-2025
    • 12.2 Islet Amyloid Polypeptide Market Forecast by Product
      • 12.2.1 Global Islet Amyloid Polypeptide Sales Forecast by Product 2019-2025
      • 12.2.2 Global Islet Amyloid Polypeptide Revenue Forecast by Product 2019-2025
    • 12.3 Islet Amyloid Polypeptide Market Forecast by End User
    • 12.4 North America Islet Amyloid Polypeptide Forecast
    • 12.5 Europe Islet Amyloid Polypeptide Forecast
    • 12.6 Asia Pacific Islet Amyloid Polypeptide Forecast
    • 12.7 Central & South America Islet Amyloid Polypeptide Forecast
    • 12.8 Middle East and Africa Islet Amyloid Polypeptide Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Islet Amyloid Polypeptide Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Islet Amyloid Polypeptide market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Islet Amyloid Polypeptide market based on company, product type, end user and key regions.

      This report studies the global market size of Islet Amyloid Polypeptide in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Islet Amyloid Polypeptide in these regions.
      This research report categorizes the global Islet Amyloid Polypeptide market by top players/brands, region, type and end user. This report also studies the global Islet Amyloid Polypeptide market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Adocia SAS
      AstraZeneca Plc
      Eli Lilly and Co
      Neurimmune Holding AG
      Nordic Bioscience A/S
      Prothena Corp Plc
      reMYND NV
      Zealand Pharma AS

      Market size by Product
      AC-253
      DACRA-042
      DACRA-089
      KBP-056
      KBP-088
      Others
      Market size by End User
      Metabolic Disorders
      Gastrointestinal
      Musculoskeletal Disorders
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Islet Amyloid Polypeptide market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Islet Amyloid Polypeptide market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Islet Amyloid Polypeptide companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Islet Amyloid Polypeptide submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Islet Amyloid Polypeptide are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Islet Amyloid Polypeptide market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now